In the past decade, substantial advances have been made in understanding the biology of
tumour-associated macrophages (TAMs), and their clinical relevance is emerging. A …

Neutrophils are the first responders to infection and inflammation and are thus a critical
component of innate immune defense. Understanding the behavior of neutrophils as they …

Neutrophils accumulate in solid tumors, and their abundance correlates with poor prognosis.
Neutrophils are not homogeneous, however, and could play different roles in cancer …

Single-cell and spatial transcriptomic technologies have revealed an underappreciated
heterogeneity of liver macrophages. This has led us to rethink the involvement of …

Effective delivery of therapeutic and diagnostic nanoparticles is dependent on their ability to
accumulate in diseased tissues. However, most nanoparticles end up in liver macrophages …

Therapeutic use of agonistic anti-CD40 antibodies is a potentially powerful approach for
activation of the immune response to eradicate tumors. However, the translation of this …

Immunotherapy is one of the most promising clinical modalities for the treatment of
malignant tumors and has shown excellent therapeutic outcomes in clinical settings …

Myeloid cells are abundant, create a highly immunosuppressive environment in
glioblastoma (GBM), and thus contribute to poor immunotherapy responses. Based on the …

The clinical use of anti-CD40 agonist monoclonal antibodies (mAbs) is aimed at recruiting
the immune system to fight the tumor cells. This approach has been demonstrated to be …

Highlights•Tissue-resident macrophages are a potent source of TAMs.•TRM–TAMs exhibit
diverse functional properties across different cancers.•Tissue context and spatial territories …